IMMUNITYBIO, INC. (IBRX) Operating margin 2016–2025
IMMUNITYBIO, INC. (IBRX) operating margin by fiscal year — reported operating income divided by reported revenue.
-226.0%FY2025 · since FY2016: -282954.5% → -226.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -226.0% | +2108.2 pp |
| FY2024 | -2334.2% | +55905.3 pp |
| FY2023 | -58239.5% | +88134.6 pp |
| FY2022 | -146374.2% | -111012.3 pp |
| FY2021 | -35361.9% | +1147.2 pp |
| FY2020 | -36509.1% | -29413.2 pp |
| FY2019 | -7095.9% | +202242.4 pp |
| FY2018 | -209338.3% | +10928.4 pp |
| FY2017 | -220266.7% | +62687.9 pp |
| FY2016 | -282954.5% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice